{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:56:52Z","timestamp":1777881412550,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.7759\/cureus.108059","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:42:12Z","timestamp":1777596132000},"source":"Crossref","is-referenced-by-count":0,"title":["Diabetic Ketoacidosis From Health Insurance-Requested Non-medical Switching"],"prefix":"10.7759","author":[{"given":"Ahmet S","family":"Can","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Forrest","family":"Yeakley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.974","article-title":"SAT109 Diabetic ketoacidosis due to non-medical switching","volume":"7","author":"Can AS","year":"2023","unstructured":"Can AS, Zhang Z, Yeakley F. SAT109 Diabetic ketoacidosis due to non-medical switching. J Endocr Soc. 2023, 7:bvad114.974. 10.1210\/jendso\/bvad114.974","journal-title":"J Endocr Soc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/0125899775246113231018080526","article-title":"Clinical similarity of biosimilars and reference drugs: A comprehensive review and new hope for public health in a new frontier","volume":"17","author":"Adatiya MD","year":"2025","unstructured":"Adatiya MD, Devani AA, Dudhia VN, Chorawala MR, Patel VN, Patel MP. Clinical similarity of biosimilars and reference drugs: A comprehensive review and new hope for public health in a new frontier. Curr Drug Res Rev. 2025, 17:41-58. 10.2174\/0125899775246113231018080526","journal-title":"Curr Drug Res Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00998-3","article-title":"Economic impact of non-medical switching from originator biologics to biosimilars: A systematic literature review","volume":"36","author":"Liu Y","year":"2019","unstructured":"Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M. Economic impact of non-medical switching from originator biologics to biosimilars: A systematic literature review. Adv Ther. 2019, 36:1851-77. 10.1007\/s12325-019-00998-3","journal-title":"Adv Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.15406\/jdmdc.2017.04.00123","article-title":"Position on non-medical switching for diabetes patients","volume":"4","author":"Ellingson L","year":"2017","unstructured":"Ellingson L. Position on non-medical switching for diabetes patients. J Diabetes Metab Disord Control. 2017, 4:138-9. 10.15406\/jdmdc.2017.04.00123","journal-title":"J Diabetes Metab Disord Control"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/18-033","article-title":"The unmet challenge of medication nonadherence","volume":"22","author":"Kleinsinger F","year":"2018","unstructured":"Kleinsinger F. The unmet challenge of medication nonadherence. Perm J. 2018, 22:18-033. 10.7812\/TPP\/18-033","journal-title":"Perm J"},{"key":"ref6","unstructured":"Lilly. How much should I expect to pay for Basaglar\u00ae (insulin glargine). Accessed. June 19, 2022: https:\/\/www.lillypricinginfo.com\/basaglar."},{"key":"ref7","unstructured":"U.S. Pharmacist. FDA Approves First Interchangeable Biosimilar Insulin for Diabetes Treatment. Accessed. June 19, 2022: https:\/\/www.uspharmacist.com\/article\/fda-approves-first-interchangeable-biosimilar-insulin-for-diabetes-treatment."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-021-00127-6","article-title":"Recurrent DKA results in high societal costs - A retrospective study identifying social predictors of recurrence for potential future intervention","volume":"7","author":"Lyerla R","year":"2021","unstructured":"Lyerla R, Johnson-Rabbett B, Shakally A, Magar R, Alameddine H, Fish L. Recurrent DKA results in high societal costs - A retrospective study identifying social predictors of recurrence for potential future intervention. Clin Diabetes Endocrinol. 2021, 7:13. 10.1186\/s40842-021-00127-6","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00190-7","article-title":"Nonmedical switching from originators to biosimilars: Does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?","volume":"7","author":"Fleischmann R","year":"2020","unstructured":"Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: Does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology?. Rheumatol Ther. 2020, 7:35-64. 10.1007\/s40744-019-00190-7","journal-title":"Rheumatol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1467887","article-title":"The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population","volume":"34","author":"Blonde L","year":"2018","unstructured":"Blonde L, Burudpakdee C, Divino V, Bookhart B, Cai J, Pfeifer M, Coleman CI. The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population. Curr Med Res Opin. 2018, 34:1501-11. 10.1080\/03007995.2018.1467887","journal-title":"Curr Med Res Opin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2024.89626","article-title":"Utilization management and physician burnout","volume":"30","author":"Struthers A","year":"2024","unstructured":"Struthers A, Chapman MA, Charles PD, Conschafter A, Cooper J, Clingham G. Utilization management and physician burnout. Am J Manag Care. 2024, 30:561-6. 10.37765\/ajmc.2024.89626","journal-title":"Am J Manag Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1738637","article-title":"Specialist physician perspectives on non-medical switching of prescription medications","volume":"8","author":"Costa OS","year":"2020","unstructured":"Costa OS, Salam T, Duhig A, et al.. Specialist physician perspectives on non-medical switching of prescription medications. J Mark Access Health Policy. 2020, 8:1738637. 10.1080\/20016689.2020.1738637","journal-title":"J Mark Access Health Policy"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1465904","article-title":"Consequences of non-medical switch among patients with type 2 diabetes","volume":"34","author":"Flores NM","year":"2018","unstructured":"Flores NM, Patel CA, Bookhart BK, Bacchus S. Consequences of non-medical switch among patients with type 2 diabetes. Curr Med Res Opin. 2018, 34:1475-81. 10.1080\/03007995.2018.1465904","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S242215","article-title":"The impact of a forced non-medical switch of inhaled respiratory medication among patients with asthma or chronic obstructive pulmonary disease: A patient survey on experience with switch, therapy satisfaction, and disease control","volume":"14","author":"Gilbert I","year":"2020","unstructured":"Gilbert I, Wada K, Burudpakdee C, Ghai C, Tan L. The impact of a forced non-medical switch of inhaled respiratory medication among patients with asthma or chronic obstructive pulmonary disease: A patient survey on experience with switch, therapy satisfaction, and disease control. Patient Prefer Adherence. 2020, 14:1463-75. 10.2147\/PPA.S242215","journal-title":"Patient Prefer Adherence"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2025.05.023","article-title":"Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching","volume":"24","author":"Aghajani M","year":"2026","unstructured":"Aghajani M, Pham J, Sholji T, Burrell K, Kok C, Frew JW. Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching. JAAD Int. 2026, 24:9-15. 10.1016\/j.jdin.2025.05.023","journal-title":"JAAD Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab099","article-title":"Multiple switches from the originator Infliximab to biosimilars is effective and safe in inflammatory bowel disease: A prospective multicenter cohort study","volume":"28","author":"Hanzel J","year":"2022","unstructured":"Hanzel J, Jansen JM, Ter Steege RW, Gecse KB, D'Haens GR. Multiple switches from the originator Infliximab to biosimilars is effective and safe in inflammatory bowel disease: A prospective multicenter cohort study. Inflamm Bowel Dis. 2022, 28:495-501. 10.1093\/ibd\/izab099","journal-title":"Inflamm Bowel Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25610","article-title":"\u200bDid a non-medical biosimilar switching policy cause an increase in non-biologic\/biosimilar health care resource utilization or cost in patients with inflammatory arthritis?","volume":"78","author":"Dang H","year":"2026","unstructured":"Dang H, Blitz S, Bansback N, Law M, Harrison M. \u200bDid a non-medical biosimilar switching policy cause an increase in non-biologic\/biosimilar health care resource utilization or cost in patients with inflammatory arthritis?. Arthritis Care Res (Hoboken). 2026, 78:296-302. 10.1002\/acr.25610","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1923467","article-title":"A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-na\u00efve patients and in patients undergoing non-medical switch from originator","volume":"37","author":"Giunta A","year":"2021","unstructured":"Giunta A, Zangrilli A, Bavetta M, Manfreda V, Pensa C, Bianchi L. A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-na\u00efve patients and in patients undergoing non-medical switch from originator. Curr Med Res Opin. 2021, 37:1099-102. 10.1080\/03007995.2021.1923467","journal-title":"Curr Med Res Opin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa834","article-title":"Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis","volume":"60","author":"Melville AR","year":"2021","unstructured":"Melville AR, Md Yusof MY, Fitton J, et al.. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2021, 60:3679-88. 10.1093\/rheumatology\/keaa834","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab027","article-title":"Effectiveness and safety of nonmedical switch from adalimumab originator to SB5 biosimilar in patients with inflammatory bowel diseases: Twelve-month follow-up from the TABLET Registry","volume":"28","author":"Tapete G","year":"2022","unstructured":"Tapete G, Bertani L, Pieraccini A, et al.. Effectiveness and safety of nonmedical switch from adalimumab originator to SB5 biosimilar in patients with inflammatory bowel diseases: Twelve-month follow-up from the TABLET Registry. Inflamm Bowel Dis. 2022, 28:62-9. 10.1093\/ibd\/izab027","journal-title":"Inflamm Bowel Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/481686-diabetic-ketoacidosis-from-health-insurance-requested-non-medical-switching","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:42:13Z","timestamp":1777596133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/481686-diabetic-ketoacidosis-from-health-insurance-requested-non-medical-switching"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.108059","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}